Delivery Order 75F40120D00032-75F40120F19004

This delivery order against the Department of Health and Human Services Food and Drug Administration is for the purpose of obtaining currently marketed drug products for FDA research studies. Awarded on September 30, 2020 to We Pharma, Inc. located in Morrisville, North Carolina, this firm fixed price contract has a potential value of $246,754.22 and period of performance through September 29, 2021. No set-aside designation was applied. We Pharma Inc. will provide the requested drug products...

The Department of Health and Human Services Food and Drug Administration awarded a $250,000 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. Performance will take place in Morrisville, North Carolina through September 2021. No set-aside designation was applied to this award made under an unidentified contracting vehicle. The prime contractor will...

This delivery order, awarded by the Department of Health and Human Services' Food and Drug Administration, is for $240,000 worth of pharmaceutical products to support domestic manufacturing and regulatory purposes. We Pharma, Inc. will provide the products in Takoma Park, Maryland by September 30, 2023 under a firm fixed price arrangement. As the FDA works to ensure the safety and effectiveness of drugs and medical devices, this contract will help the agency assess pharmaceutical manufacturing...

This is a firm-fixed-price delivery order awarded to We Pharma, Inc., a self-certified small disadvantaged business, by the Food and Drug Administration (FDA) under an Indefinite Delivery Contract (IDC). The purpose of this $399,561.18 award is to provide pharmaceutical drug products to support the FDA's research studies, regulatory activities, and emergency response needs. The contract has an ultimate completion date of August 6, 2024. This delivery order is not set-aside and is part of two...

The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a firm-fixed price delivery order to We Pharma, Inc., doing business as WEP Clinical, to obtain a reliable source of currently marketed drug products to support FDA research studies for the Generic Drug User Fee Amendments (GDUFA) regulatory science program. The $477,943.82 order, which has no set-aside designation, is part of a larger 5-year, $9.5 million indefinite delivery contract awarded to We...

We Pharma, Inc. doing business as WEP Clinical has been awarded a firm fixed price delivery order valued at $2,000,000 by the Department of Health and Human Services' Food and Drug Administration (HHS FDA) to provide pharmaceutical products and services in support of FDA operations. This task order was issued against We Pharma's existing indefinite delivery contract with HHS FDA, valued at $6 million over five years, to supply drug products and emergency delivery services for FDA research and...

The Department of Health and Human Services Food and Drug Administration awarded a $145,636.17 firm fixed price delivery order to We Pharma, Inc. of Silver Spring, Maryland for pharmaceutical products to support domestic manufacturing. No set-aside provisions were applied to this contract. We Pharma will provide the FDA's Office of Pharmaceutical Quality with domestic pharmaceutical manufacturing supplies through September 30th, 2022 at their Silver Spring location. As the regulatory body...

This firm-fixed-price purchase order was awarded by the Food and Drug Administration (FDA), a civilian agency under the Department of Health and Human Services, to We Pharma, Inc., a self-certified small disadvantaged business. The $214,914.90 contract is for the provision of "PHYSICOCHEMICAL PRODUCTS" and has a total small business set-aside. The award supports the FDA's regulatory science program and provides pharmaceutical drug products for the agency's research, compliance, and...

This is a firm-fixed-price delivery order awarded by the Food and Drug Administration (FDA) to We Pharma, Inc., doing business as WEP Clinical, a self-certified small disadvantaged business. The $607,060.00 contract is to obtain a reliable source of currently marketed drug products to support the FDA's Generic Drug User Fee Amendments (GDUFA) regulatory science program within the Office of Pharmaceutical Quality Research (OPQR). The contract has an ultimate completion date of August 6, 2030....

This is a delivery order awarded by the Food and Drug Administration (FDA) to We Pharma, Inc., a self-certified small disadvantaged business structured as a limited liability company. The contract, valued at $357,000.00, is for the provision of pharmaceutical drug products to support the FDA's various research, regulatory, and emergency response activities. We Pharma, doing business as WEP Clinical, holds two significant Indefinite Delivery Contracts (IDCs) with the FDA, totaling $9.5 million...